Ilex Medical

Ilex Medical EBIT per Share

The EBIT per Share of Ilex Medical (ILX.TA) as of Oct 22, 2026 is 5.89 ILS. In the previous year, EBIT per Share was 7.36 ILS — a change of -19.96% (lower).

EBIT per Share

5.89ILS

YoY

-19.96%

Last updated:

EBIT per Share of Ilex Medical is 2024 5.89 ILS. EBIT per Share of Ilex Medical was 2023 7.36 ILS. It decreases by -19.96% lower compared to the previous year.

The Ilex Medical EBIT per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Share
Date
EBIT per Share
Jan 1, 2017
5.32 ILS
Jan 1, 2018
7.55 ILS
Jan 1, 2019
8.26 ILS
Jan 1, 2020
14.02 ILS
Jan 1, 2021
22.79 ILS
Jan 1, 2022
12.54 ILS
Jan 1, 2023
7.36 ILS
Jan 1, 2024
5.89 ILS
The Ilex Medical EBIT per Share history
YEAREBIT per ShareYoY
5.89ILS-19.96%
7.36ILS-41.29%
12.54ILS-44.96%
22.79ILS+62.56%
14.02ILS+69.74%
8.26ILS+9.31%
7.55ILS+42.02%
5.32ILS+6.85%
4.98ILS-7.89%
5.40ILS+28.65%
4.20ILS+14.17%
3.68ILS-4.42%
3.85ILS-30.00%
5.50ILS+49.05%
3.69ILS-8.66%
4.04ILS+26.25%
3.20ILS+39.13%
2.30ILS+27.07%
1.81ILS+36.45%
1.33ILS—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Ilex Medical Stock analysis

What does Ilex Medical do? Ilex Medical Ltd supplies in vitro diagnostic equipment and laboratory management software, targeting healthcare providers and laboratories. The company offers nucleic acid testing (NAT) blood screening solutions, cancer screening products, retro virus load monitoring, TB and STD testing systems, and blood sugar monitoring devices. Its subsidiaries include Ilex South Africa, Orsyx-LIS, Ilex BioTech Ltd, and Medtechnica Ltd, which support its diagnostic equipment and software distribution. Healthcare facilities and diagnostic laboratories purchase these products for clinical testing and patient management. Ilex Medical Ltd's revenue streams come from selling diagnostic equipment, reagent systems, and laboratory information systems (LIS) to healthcare institutions. The firm's NAT blood screening solutions and infectious disease testing systems are key products for blood banks and public health labs. Subsidiaries like Orsyx-LIS provide specialized laboratory management software, enhancing the company's offerings in the diagnostic software segment. Hospitals and clinics rely on these solutions for efficient diagnostic workflows. The company serves segments including hospitals, blood banks, public health laboratories, and clinics focused on infectious disease management. Products such as cancer screening tools and retro virus load systems are sold to specialized medical facilities. Ilex South Africa and Medtechnica Ltd extend the company's reach in regional markets, supporting localized sales and service. Diagnostic software from Orsyx-LIS is integrated into laboratory workflows for improved data management. Ilex Medical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Ilex Medical stock

EBIT per Share of Ilex Medical is 5.89 ILS in 2024.

EBIT per Share of Ilex Medical changed from 7.36 ILS to 5.89 ILS, representing a -19.96% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Share Ilex Medical since 2006 – with annual values, charts, and detailed analysis.

EBIT per Share measures operating profit allocated to each outstanding share.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Ilex Medical

All Key Metrics — Ilex Medical